ASCO in Action: FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs

On April 13, the U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy.

No comments have been posted yet.